Enteric coated risedronate 35mg for the treatment of osteoporosis

Description

In this Product Explainer, Endocrinologist Prof Ego Seeman explains the role of enteric coated risedronate 35mg for the treatment of osteoporosis (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof Ron Dick

A/Prof Ron Dick

Why is LDL control important?

Prof Carol Wham

Prof Carol Wham

Malnutrition and frailty in older adults - The importance of screening and early intervention

Prof Andrew Sindone

Prof Andrew Sindone

Heart failure and obesity - Which do we manage first?

Brett Lee

Brett Lee

The social media ban - Practical preparation for children and family

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Ego Seeman

expert

Prof Ego Seeman

Endocrinologist; Dept of Medicine and Endocrinology, Austin Health, University of Melbourne; Editor, Progress in Osteoporosis

Date published: 7 November 2023